pantoprazole has been researched along with Duodenal Diseases in 2 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wauters, L | 1 |
| Ceulemans, M | 1 |
| Frings, D | 1 |
| Lambaerts, M | 1 |
| Accarie, A | 1 |
| Toth, J | 1 |
| Mols, R | 1 |
| Augustijns, P | 1 |
| De Hertogh, G | 1 |
| Van Oudenhove, L | 1 |
| Tack, J | 1 |
| Vanuytsel, T | 1 |
| Pilotto, A | 1 |
| Di Mario, F | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Battaglia, G | 1 |
| Germanà , B | 1 |
| Marin, R | 1 |
| Valerio, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients[NCT03545243] | Phase 4 | 79 participants (Actual) | Interventional | 2018-04-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pantoprazole and Duodenal Diseases
| Article | Year |
|---|---|
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Aging; Amoxicillin; Anti-Bacterial Agent | 2000 |
1 other study available for pantoprazole and Duodenal Diseases
| Article | Year |
|---|---|
Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.
Topics: Adult; Belgium; Bile Acids and Salts; Case-Control Studies; Duodenal Diseases; Duodenum; Dyspepsia; | 2021 |